Snipr Biome brings first candidate to human trial
Danish CRISPR company Snipr Biome has started a phase I study of drug candidate SNIPR001, which is designed to treat E.coli infections in the gut, and is expecting the first data toward the end of the year.
by albert rønning-andersson, translated by daniel pedersen
Copenhagen-based CRISPR company Snipr Biome has formally initiated a placebo-controlled phase I trial with a potential treatment for E. coli infections in the gut, and has dosed the first, healthy person, the company has announced in a press release on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Snipr Biome chose clinical debut in CRISPR-ready USA
For subscribers
Snipr Biome expands executive management team
For subscribers
Snipr Biome CEO delighted over FDA fast-track status
For subscribers
.jpg&w=384&q=75)
